nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Browsing articles in "ADHD"

 

FDA Approves Nonstimulant Option For Adults With ADHD
April 29, 2022   

The U.S. Food and Drug Administration approved an expanded indication for viloxazine extended-release capsules for the treatment of attention deficit hyperactivity disorder in adult patients aged 18 and older, making it the first novel, nonstimulant option for adults with ADHD in 20 years. ...
 Continue reading
Early Life Stress and ADHD
April 5, 2022   

In a recent study, the relationship between hypothalamic-pituitary-adrenal (HPA) axis disruption and childhood maltreatment on cognitive functioning in adolescents with attention deficit hyperactivity disorder (ADHD) was examined...
 Continue reading (Members only)
Generalized Anxiety Disorder Among Adults With Attention-Deficit Hyperactivity Disorder
December 13, 2021   

Attention-deficit hyperactivity disorder and generalized anxiety disorder are highly comorbid; however, there are several potential confounding factors that must be accounted for to determine the degree of their association. Data from a nationally representative cross-sectional survey...
 Continue reading (Members only)
2021 NEI Congress Young Investigator Poster Competition Winners
November 5, 2021   

The 2021 NEI Congress Scientific Poster Session and Reception was held on Friday, November 5th and featured 67 posters, with an additional 48 posters presented virtually, covering the full spectrum of mental health research and clinical data. Among them, three particularly stood out for the quality of their data and contributions to the field, and...
 Continue reading
ADHD and Alzheimer’s Disease Across Generations
September 25, 2021   

Due to previous conflicting results regarding the association between attention-deficit hyperactivity disorder (ADHD) and Alzheimer’s disease (AD), a recent nationwide cohort study evaluated their link across generations. Index persons (N=2,132,929) born in Sweden were linked to their biological relatives: 4,246,182 index person-parent pairs....
 Continue reading (Members only)
Factors Associated With Stimulant Treatment Outcomes in ADHD
July 9, 2021   

Stimulant medications are the first-line recommended treatment for attention deficit hyperactivity disorder (ADHD); however, many patients discontinue treatment or switch to nonstimulant ADHD medications. A recent study investigated the genetic, clinical, and sociodemographic factors that influence stimulant treatment initiation, discontinuation, and switch to nonstimulant medications in ADHD. The study included...
 Continue reading
FDA Approves New Treatment For ADHD In Pediatric Patients
April 2, 2021   

A U.S. Food and Drug Administration approves viloxazine extended-release capsules for the treatment of attention-deficit hyperactivity disorder in pediatric patients 6 to 17 years of age...
 Continue reading
FDA Approves New Once-Daily Treatment for ADHD
March 17, 2021   

The US Food and Drug Administration has approved a new, once-daily oral stimulant medication for treatment of attention deficit hyperactivity disorder (ADHD) in people aged 6 years and older. The new drug consists of a novel prodrug co-formulated with...
 Continue reading
Youth With ADHD May Have Increased Risk for Psychotic Disorders
March 8, 2021   

In a recent meta-analysis of 12 studies and 1.85 million participants, an increased risk of psychotic disorder was associated with a diagnosis of attention deficit hyperactivity disorder during childhood compared to participants without attention deficit hyperactivity disorder during childhood....
 Continue reading
Children With Congenital Heart Disease at Elevated Risk of Depression, Anxiety, ADHD
January 26, 2021   

A recent comparative cross-sectional study was conducted to examine the risk of mental health disorders (e.g. depression, anxiety, and attention deficit/hyperactivity disorder) in youth with congenital heart disease (CHD). Data was collected from...
 Continue reading (Members only)
12345
Top of Page